Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

  • ID: 4530578
  • Report
  • Region: Global
  • 82 Pages
  • GBI Research
1 of 4

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Ansun Biopharma Inc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Navigen Inc
  • TechnoVax Inc
  • MORE

RSV infects the lungs and breathing passages. Symptoms include cough, stuffy or runny nose, mild sore throat, earache and fever. There are 127 products in development for RSV infections and key companies operating in this pipeline space include Johnson & Johnson, MedImmune and ReViral.

HPIV-3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough runny nose, croup, bronchiolitis, wheezing and sore throat. There are five products in development for HPIV-3 infections and companies operating in this pipeline space include Ansun Biopharma and Amarillo Biosciences.

Molecular targets present in the RSV and HPIV-3 pipeline landscapes include exo alpha sialidase and fatty acid synthase.

This report “Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3). It comprehensively documents therapeutics under development for RSV and HPIV-3 infections, and features dormant and discontinued products.

Scope

  • Which companies are the most active within the pipeline for RSV and HPIV-3 infections?
  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened within this field?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • Ansun Biopharma Inc
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Navigen Inc
  • TechnoVax Inc
  • MORE

1 Table of Contents

2 Introduction
2.1 Report Coverage
2.2 Respiratory Syncytial Virus (RSV) Infections – Overview
2.3 Human Parainfluenza Virus 3 Infections – Overview

3 Therapeutics Development
3.1 Respiratory Syncytial Virus (RSV) Infections
3.2 Human Parainfluenza Virus 3 Infections

4 Therapeutics Assessment
4.1 Respiratory Syncytial Virus (RSV) Infections
4.2 Human Parainfluenza Virus 3 Infections

5 Companies Involved in Therapeutics Development
5.1 Respiratory Syncytial Virus (RSV) Infections
5.2 Human Parainfluenza Virus 3 Infections

6 Dormant Projects
6.1 Respiratory Syncytial Virus (RSV) Infections
6.2 Human Parainfluenza Virus 3 Infections

7 Discontinued Products
7.1 Respiratory Syncytial Virus (RSV) Infections
7.2 Human Parainfluenza Virus 3 Infections

8 Product Development Milestones
8.1 Respiratory Syncytial Virus (RSV) Infections

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation

List of Tables
Table 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections
Table 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections
Table 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections
Table 4: Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections
Table 5: Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections
Table 6: Number of Products under Development for Human Parainfluenza Virus 3 Infections
Table 7: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections
Table 8: Number of Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections
Table 9: Products under Development by Companies, Human Parainfluenza Virus 3 Infections
Table 10: Products under Development by Universities/Institutes, Human Parainfluenza Virus 3 Infections
Table 11: Number of Products by Stage and Target, Respiratory Syncytial Virus (RSV) Infections
Table 12: Number of Products by Stage and Mechanism of Action, Respiratory Syncytial Virus (RSV) Infections
Table 13: Number of Products by Stage and Route of Administration, Respiratory Syncytial Virus (RSV) Infections
Table 14: Number of Products by Stage and Molecule Type, Respiratory Syncytial Virus (RSV) Infections
Table 15: Number of Products by Stage and Target, Human Parainfluenza Virus 3 Infections
Table 16: Number of Products by Stage and Mechanism of Action, Human Parainfluenza Virus 3 Infections
Table 17: Number of Products by Stage and Route of Administration, Human Parainfluenza Virus 3 Infections
Table 18: Number of Products by Stage and Molecule Type, Human Parainfluenza Virus 3 Infections
Table 19: Respiratory Syncytial Virus (RSV) Infections – Pipeline by 3-V Biosciences Inc,
Table 20: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Abivax SA
Table 21: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Ablynx NV
Table 22: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ADMA Biologics Inc
Table 23: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Agilvax Inc
Table 24: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Amarillo Biosciences Inc
Table 25: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Anima Biotech Ltd
Table 26: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Aridis Pharmaceuticals LLC
Table 27: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Artificial Cell Technologies Inc
Table 28: Respiratory Syncytial Virus (RSV) Infections – Pipeline by AstraZeneca Plc
Table 29: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Bavarian Nordic A/S
Table 30: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Celltrion Inc
Table 31: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Curevac AG
Table 32: Respiratory Syncytial Virus (RSV) Infections – Pipeline by DBV Technologies SA
Table 33: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Enanta Pharmaceuticals Inc
Table 34: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Evec Inc
Table 35: Respiratory Syncytial Virus (RSV) Infections – Pipeline by F. Hoffmann-La Roche Ltd
Table 36: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gene Techno Science Co Ltd
Table 37: Respiratory Syncytial Virus (RSV) Infections – Pipeline by GenVec Inc
Table 38: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Gilead Sciences Inc
Table 39: Respiratory Syncytial Virus (RSV) Infections – Pipeline by GlaxoSmithKline Plc
Table 40: Respiratory Syncytial Virus (RSV) Infections – Pipeline by iBio Inc
Table 41: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunovaccine Inc
Table 42: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Immunwork Inc
Table 43: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Inovio Pharmaceuticals Inc
Table 44: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Johnson & Johnson
Table 45: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Karyopharm Therapeutics Inc
Table 46: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Kineta Inc
Table 47: Respiratory Syncytial Virus (RSV) Infections – Pipeline by mAbxience SA
Table 48: Respiratory Syncytial Virus (RSV) Infections – Pipeline by MedImmune LLC
Table 49: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Medivir AB
Table 50: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Mymetics Corp
Table 51: Respiratory Syncytial Virus (RSV) Infections – Pipeline by NanoBio Corp
Table 52: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Navigen Inc
Table 53: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Novavax Inc
Table 54: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Phoenix Biotechnology Inc
Table 55: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Profectus BioSciences Inc
Table 56: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Pulmocide Ltd
Table 57: Respiratory Syncytial Virus (RSV) Infections – Pipeline by ReViral Ltd
Table 58: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Romark Laboratories LC
Table 59: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Takeda Pharmaceutical Co Ltd
Table 60: Respiratory Syncytial Virus (RSV) Infections – Pipeline by TechnoVax Inc
Table 61: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Themis Bioscience GmbH
Table 62: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vault Pharma Inc
Table 63: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Vaxart Inc
Table 64: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Virometix AG
Table 65: Respiratory Syncytial Virus (RSV) Infections – Pipeline by Visterra Inc
Table 66: Respiratory Syncytial Virus (RSV) Infections – Pipeline by VLP Biotech Inc
Table 67: Human Parainfluenza Virus 3 Infections – Pipeline by 3-V Biosciences Inc
Table 68: Human Parainfluenza Virus 3 Infections – Pipeline by Amarillo Biosciences Inc
Table 69: Human Parainfluenza Virus 3 Infections – Pipeline by Ansun Biopharma Inc
Table 70: Human Parainfluenza Virus 3 Infections – Pipeline by Moderna Therapeutics Inc
Table 71: Respiratory Syncytial Virus (RSV) Infections – Dormant Projects
Table 72: Human Parainfluenza Virus 3 Infections – Dormant Projects
Table 73: Respiratory Syncytial Virus (RSV) Infections – Discontinued Products
Table 74: Human Parainfluenza Virus 3 Infections – Discontinued Products

List of Figures
Figure 1: Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections
Figure 2: Number of Products under Development by Companies, Respiratory Syncytial Virus (RSV) Infections
Figure 3: Number of Products under Development by Universities/Institutes, Respiratory Syncytial Virus (RSV) Infections
Figure 4: Number of Products under Development for Human Parainfluenza Virus 3 Infections
Figure 5: Number of Products under Development by Companies, Human Parainfluenza Virus 3 Infections
Figure 6: Number of Products by Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections
Figure 7: Number of Products by Stage and Top 10 Targets, Respiratory Syncytial Virus (RSV) Infections
Figure 8: Number of Products by Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections
Figure 9: Number of Products by Stage and Top 10 Mechanism of Actions, Respiratory Syncytial Virus (RSV) Infections
Figure 10: Number of Products by Routes of Administration, Respiratory Syncytial Virus (RSV) Infections
Figure 11: Number of Products by Stage and Routes of Administration, Respiratory Syncytial Virus (RSV) Infections
Figure 12: Number of Products by Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections
Figure 13: Number of Products by Stage and Top 10 Molecule Types, Respiratory Syncytial Virus (RSV) Infections
Figure 14: Number of Products by Targets, Human Parainfluenza Virus 3 Infections
Figure 15: Number of Products by Stage and Targets, Human Parainfluenza Virus 3 Infections
Figure 16: Number of Products by Mechanism of Actions, Human Parainfluenza Virus 3 Infections
Figure 17: Number of Products by Stage and Mechanism of Actions, Human Parainfluenza Virus 3 Infections
Figure 18: Number of Products by Top 10 Routes of Administration, Human Parainfluenza Virus 3 Infections
Figure 19: Number of Products by Stage and Routes of Administration, Human Parainfluenza Virus 3 Infections
Figure 20: Number of Products by Molecule Types, Human Parainfluenza Virus 3 Infections
Figure 21: Number of Products by Stage and Molecule Types, Human Parainfluenza Virus 3 Infections

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 3-V Biosciences Inc
  • Abivax SA
  • Ablynx NV
  • ADMA Biologics Inc
  • Agilvax Inc
  • Amarillo Biosciences Inc
  • Anima Biotech Ltd
  • Ansun Biopharma Inc
  • Aridis Pharmaceuticals LLC
  • Artificial Cell Technologies Inc
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Celltrion Inc
  • Curevac AG
  • DBV Technologies SA
  • Enanta Pharmaceuticals Inc
  • Evec Inc
  • F. Hoffmann-La Roche Ltd
  • Gene Techno Science Co Ltd
  • GenVec Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • iBio Inc
  • Immunovaccine Inc
  • Immunwork Inc
  • Inovio Pharmaceuticals Inc
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • Kineta Inc
  • mAbxience SA
  • MedImmune LLC
  • Medivir AB
  • Mymetics Corp
  • NanoBio Corp
  • Navigen Inc
  • Novavax Inc
  • Phoenix Biotechnology Inc
  • Profectus BioSciences Inc
  • Pulmocide Ltd
  • ReViral Ltd
  • Romark Laboratories LC
  • Takeda Pharmaceutical Co Ltd
  • TechnoVax Inc
  • Themis Bioscience GmbH
  • Vault Pharma Inc
  • Vaxart Inc
  • Virometix AG
  • Visterra Inc
  • VLP Biotech Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll